Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 232 clinical trials
  • 0 views
  • 19 Feb, 2024
  • 2 locations
  • 0 views
  • 19 Feb, 2024
PCSK9i in AAA123  

Please see section 3 of the full protocol Please see section 3 of the full protocol Please see section 3 of the full protocol

  • 0 views
  • 18 Mar, 2025
  • 1 location
Trial v7.2.1 PS Check  

Trial v7.2.1 PS Check

  • 0 views
  • 19 Jun, 2025
  • 1 location
FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma

Patients with resectable adenocarcinoma of the stomach or the esophagogastric junction (II-III type by Siewert) without previous therapy will be treated with one of two chemotherapy combinations before and after surgery. One half of the patients gets 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Docetaxel (FLOT), the others 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin …

HIV Infection
irinotecan
absolute neutrophil count
gastric tumor
hepatitis
  • 0 views
  • 19 Feb, 2024
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT …

prostate specific antigen
cancer
prostate cancer
castration-resistant prostate cancer
lymphadenopathy
  • 0 views
  • 19 Feb, 2024
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R or Chronic Myelomonocytic Leukemia-2 (CMML-2)

This is a Phase III multi-center, randomized, two-arm parallel-group, double-blind, placebo-controlled study of MBG453 or placebo added to azacitidine in adult subjects with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) who have an indication for treatment with azacitidine in first-line …

stem cell transplantation
cell transplantation
chronic myelomonocytic leukemia
leukemia
cmml-2
  • 0 views
  • 19 Feb, 2024
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Primary Objectives: Safety run-in: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM) Randomized Phase 3: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival when compared to …

multiple myeloma
minimal residual disease
bone marrow procedure
lenalidomide
residual tumor
  • 0 views
  • 19 Feb, 2024
  • 16 locations
Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC

This study evaluates the addition of nivolumab to TACE/TAE in the treatment of patients with intermediate stage hepatocellular carcinoma. All patients will receive TACE/TAE and half will receive nivolumab.

neutrophil count
carcinoma
hair thinning
vitiligo
type 1 diabetes mellitus
  • 0 views
  • 19 Feb, 2024
Venglustat in Combination With Cerezyme in Adult and Pediatric Patients With Gaucher Disease Type 3

Primary Objectives: Part 1: Cohorts 1, 2 and 3 Evaluate cerebrospinal fluid (CSF) biomarkers in adult Gaucher disease (GD) Type 3 patients that distinguish GD3 from adult Gaucher disease Type 1 (GD1) patients. Screen adult and pediatric GD3 patients who qualify for treatment with venglustat in Parts 2 and 3. …

  • 0 views
  • 19 Feb, 2024
  • 7 locations